Teva Completes Actavis Acquisition and Picks Up Anda, Inc. from Allergan

Teva Pharmaceutical Industries has completed its acquisition of Allergan’s Actavis Generics business for $40.5 billion. Teva had announced its plans to acquire Actavis in 2015, but the Federal Trade Commission had required that the Israeli company first divest 79 of its generics businesses in such areas as anesthetics, antibiotics, weight loss treatments, and oral contraceptives. Teva has sold those businesses to a list of companies that include Dr. Reddy’s, Aurobindo Pharma, Cipla, Mayne Pharma and 3M. Teva expects its new acquisition to contribute $1.9 billion in net income in 2017, according to Reuters reports.

With the acquisition, Teva reports that it will have roughly 338 product registrations awaiting FDA approval, with 115 abbreviated new drug applications (ANDAs) awaiting approval in the U.S.  After the divestitures, Teva reports, it will have a pipeline capable of over 5,000 launches in Europe.  Globally, Teva plans to introduce 1,500 generic products in 2017.

On August 3, one day after the Actavis acquisition was completed, Teva also acquired Allergan’s Anda, Inc., the fourth largest distributor of generic pharmaceuticals in the US, for $500 million.  The company is expected to generate over $1 billion in net revenue in 2016, according to Allergan. 

Source: www.businesswire.com/news/home/20160802006666/en/